LIQUIDIA CORP

LQDA13 Dec 2024
Healthcare
$11
+0.01 (+0.64%)
Lowest Today
$10.81
Highest Today
$11.32
Today’s Open
$11
Prev. Close
$10.94
52 Week High
$16.99
52 Week Low
$7.2
To Invest in LIQUIDIA CORP

LIQUIDIA CORP

Healthcare
LQDA13 Dec 2024
+0.01 (+0.64%)
1M
3M
6M
1Y
5Y
Low
$10.8
Day’s Range
High
$11.32
10.8
52 Week Low
$7.2
52-Week Range
52 Week High
$16.99
7.2
1 Day
-
1 Week
-0.09%
1 month return
+6.99%
3 month return
+12.34%
6 month return
-18.08%
1 Year return
+53.98%
3 Years return
+151.94%
5 Years return
+209.26%
10 Years return
-
Institutional Holdings
Caligan Partners LP
9.59
Patient Square Capital
8.49
BlackRock Inc
5.01
Vanguard Group Inc
4.07
Farallon Capital Management, L.L.C.
3.89
Findell Capital Management LLC
3.77
Kynam Capital Management, LP
2.68

Market Status

Fundamentals
Market Cap
925.92 mln
PB Ratio
8.38
PE Ratio
0
Enterprise Value
724.25 mln
Total Assets
118.33 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Organisation
LIQUIDIA CORP
Employees
145
Industry
Biotechnology
CEO
Dr. Roger A. Jeffs Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities